Phase II Trial of Pembrolizumab and All-Trans Retinoic Acid Combination for Relapsed or Refractory Hodgkin and B-Cell Non-Hodgkin Lymphoma

What this Trial Is About

Researchers are evaluating a combination treatment of all-trans retinoic acid ATRA and pembrolizumab in adults with relapsed or refractory Hodgkin Lymphoma HL or B-cell Non-Hodgkin Lymphoma B-NHL. This Phase II trial focuses on patients who have not responded to previous therapies or have experienced disease relapse. The study aims to assess safety and treatment effects in this specific lymphoma population. Participants receive pembrolizumab 200 mg every three weeks along with ATRA taken orally at a dose of 150 mgm2 for three days around each of the first four pembrolizumab infusions the day before, the day of, and the day after each infusion. This open-label trial involves one treatment arm combining these two drugs to investigate their joint impact on lymphoma. During the study, participants will be monitored for adverse events up to 90 days after treatment. Researchers will also evaluate response rates, including overall and complete remission, for up to two years following the last therapy. Blood samples will be collected at screening, before cycles 2 and 4, and shortly after cycle 4 to analyze immune cells. Participants must attend all scheduled visits and comply with study procedures throughout the trial duration.

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL